Justia Class Action Opinion Summaries

A publicly traded Delaware company specializing in plant-based sweeteners became the subject of a merger transaction led by the controlling stockholder of a major suitor, who was also the father of the company’s CEO. Shortly after becoming interim CEO, the son secretly provided his father’s investment firm with confidential and material nonpublic financial information, including a key valuation report. Over the next several months, the CEO continued to share sensitive company data with his father’s entities. The father’s investment firm then accumulated a significant ownership stake in the company and submitted an offer to acquire it. The board responded by forming a Special Committee and attempting to restrict the CEO’s involvement, but after he refused to sign a confidentiality agreement, he was placed on leave. Despite this, he was later given access to confidential board materials and attended meetings regarding the sale process.The Court of Chancery of the State of Delaware reviewed the case after the plaintiff, a stockholder, brought a class action challenging the merger and related conduct. The plaintiff alleged breaches of fiduciary duty, statutory violations under 8 Del. C. § 203, and conversion. The defendants moved to dismiss the complaint under Rule 12(b)(6). The court found that the plaintiff had adequately alleged that the board’s process was grossly negligent, noting the board’s failure to adequately wall off the conflicted CEO and its misleading proxy statement to stockholders. As a result, the statutory safe harbors under 8 Del. C. § 144(a)(1) and (a)(2) were unavailable at the pleading stage.The court held that claims could proceed against the CEO and the executive chairman, who had negotiated a lucrative consulting agreement in connection with the merger. It dismissed the remaining directors, finding them disinterested and not alleged to have acted in bad faith. The court also dismissed the statutory and conversion claims, holding that the challenged stockholder vote satisfied Section 203’s requirements and that deficiencies in the proxy statement did not render the merger invalid. View "Dodiya v. Franklin" on Justia Law

A large public pension fund alleged that a government-sponsored enterprise and three of its senior officers made false and misleading statements regarding the company’s exposure to subprime and Alt-A mortgages during a period preceding the 2008 financial crisis. The pension fund claimed that the company’s public statements and disclosures understated its exposure to high-risk loans, while internal documents and risk assessments suggested a much greater level of risk. It further argued that, when the company’s actual exposure came to light, its stock price fell, resulting in significant losses to shareholders.Previously, the United States District Court for the Northern District of Ohio denied class certification, excluded the pension fund’s expert, and granted summary judgment to the defendants. The court concluded that the pension fund failed to establish reliance due to an inability to show that the company’s stock traded in an efficient market, improperly rejected the fund’s price-maintenance theory of fraud, found insufficient evidence to support loss causation and damages, and determined the defendants did not act with scienter. The court also found no actionable misstatements regarding credit-risk and underwriting standards, and dismissed control-person liability claims after finding no underlying securities violation.On appeal, the United States Court of Appeals for the Sixth Circuit reversed in part, vacated in part, and remanded. The appellate court held that the pension fund presented sufficient evidence for a jury to find that the company made materially false or misleading statements regarding its subprime and Alt-A exposure, and that issues of scienter and reliance were present. The court determined that the lower court erred in rejecting the price-maintenance theory and improperly excluded the plaintiff’s expert. It also concluded that the fund should be allowed another opportunity to seek class certification and to present evidence of loss causation and damages. The court reinstated the underlying securities fraud and control-person liability claims for further proceedings. View "OPERS v. FHLMC" on Justia Law

Plaintiffs, who were investors in a pharmaceutical company, brought a putative class action alleging securities fraud. The company had developed a drug to treat geographic atrophy, a form of age-related macular degeneration, and conducted two large clinical trials (OAKS and DERBY) before the drug's approval by the FDA. During the class period, company representatives publicly stated that there were no observed cases of retinal vasculitis, a serious eye condition, among trial participants. After the drug's commercialization, new reports emerged of retinal vasculitis in patients treated with the drug, leading to a decline in the company’s stock price and the addition of a warning to the drug’s label.The action was initially filed in the U.S. District Court for the District of Delaware and later transferred to the U.S. District Court for the District of Massachusetts. The plaintiffs argued that the company's statements were misleading half-truths because the clinical trials were not specifically designed to detect retinal vasculitis, and this limitation was not disclosed to investors. The defendants moved to dismiss, contending that the statements were not materially misleading and that there was no sufficient allegation of scienter (intent to defraud). The U.S. District Court for the District of Massachusetts granted the motion, holding that the omissions were not actionable because the relevant trial protocols and methodologies had been publicly disclosed and disagreements over scientific methodology do not support securities fraud claims.On appeal, the United States Court of Appeals for the First Circuit affirmed the dismissal. The court held that the company’s statements were not materially misleading because the information regarding the trial protocols, including when and how retinal vasculitis could be detected, was publicly available. The court concluded that no material misrepresentation or actionable omission had occurred, and thus affirmed the district court’s judgment. View "In Re: Apellis Pharm., Inc. Securities Litigation" on Justia Law

The plaintiffs, who purchased securities issued by an animal health company, brought a proposed class action against the company and certain officers and directors. They alleged that the company misled investors by publicly attributing its sales growth to strong end-user demand, when in reality, the growth was artificially created through “channel stuffing”—the practice of pushing excessive inventory onto distributors, thus inflating reported revenues. The company’s alleged conduct took place around the time of major acquisitions and included public statements and SEC filings that, according to the plaintiffs, failed to disclose the channel stuffing and misrepresented the true basis for revenue increases.The United States District Court for the Southern District of Indiana reviewed the plaintiffs’ first amended complaint and dismissed it without prejudice for failure to state a claim, allowing an opportunity to amend. The plaintiffs sought to file a second amended complaint, asserting claims under the Securities Exchange Act of 1934 and the Securities Act of 1933, as well as related “control person” liability provisions. The district court denied leave to amend, deeming further amendment futile, and dismissed the case with prejudice. The court concluded the plaintiffs had not adequately alleged actionable misstatements, scienter (intent to defraud), or loss causation under the heightened pleading standards required by the Private Securities Litigation Reform Act and Federal Rule of Civil Procedure 9(b).On appeal, the United States Court of Appeals for the Seventh Circuit affirmed the district court’s decision. The appellate court held that, even assuming the statements at issue could be considered materially misleading, the plaintiffs failed to allege facts giving rise to a strong inference of scienter. The court also agreed that the claims under the Securities Act sounded in fraud and therefore required particularized pleading, which the plaintiffs had not met. Consequently, all claims were properly dismissed with prejudice. View "Hunter v Elanco Animal Health Incorporated" on Justia Law

A group of shareholders alleged that a major aerospace manufacturer and several of its former executives made repeated misrepresentations regarding the company’s commitment to safety following two fatal airplane crashes involving one of its aircraft models. The shareholders claimed that these false and misleading statements artificially inflated or maintained the company’s stock price. When a subsequent in-flight safety incident and other disclosures revealed ongoing safety and quality issues, the company’s stock price declined, causing significant losses for the shareholders. The lead plaintiffs, representing a proposed class, sought to recover these losses through a class action lawsuit.The United States District Court for the Eastern District of Virginia oversaw the initial proceedings. It denied the defendants’ motion to dismiss, finding the allegations sufficiently detailed, and subsequently certified a class. The district court concluded that the plaintiffs’ proposed damages methodology, which was based on an “out-of-pocket” measure, satisfied the requirements established by Rule 23 of the Federal Rules of Civil Procedure and the Supreme Court’s decision in Comcast Corp. v. Behrend. The court found that this methodology fit the plaintiffs’ theory of liability and that class-wide issues predominated over individual questions.On appeal, the United States Court of Appeals for the Fourth Circuit reviewed whether class certification was proper. The Fourth Circuit found that the plaintiffs did not provide a sufficiently specific damages methodology at the class certification stage, as required by Comcast. The court held that simply describing a general measure of damages was inadequate, and that the plaintiffs needed to commit to a particular methodology and demonstrate its consistency with their liability theory. Because the district court did not conduct the rigorous analysis required and relied on inadequate proof, the Fourth Circuit reversed the class certification order and remanded the case for further proceedings. View "In re: The Boeing Company" on Justia Law

Axsome Therapeutics, Inc., a biopharmaceutical company, developed AXS-07, an experimental migraine treatment. Beginning in late 2019, Axsome and its officers made public statements about AXS-07’s regulatory prospects and estimated filing dates for FDA approval, which plaintiffs allege were false and misleading because they omitted significant manufacturing and control deficiencies. Throughout 2020 and 2021, Axsome repeatedly delayed the expected FDA filing date for AXS-07. In April 2022, Axsome disclosed that the FDA had identified unresolved issues, causing its stock price to drop.After these disclosures, Axsome faced related litigation in the United States District Court for the Southern District of New York, including a securities class action and derivative lawsuits. The Securities Action was ultimately settled in 2026. The federal derivative suits were consolidated and stayed during the securities litigation. Meanwhile, in April and May 2025, plaintiffs in this Delaware action sent Section 220 books and records demands to Axsome, seeking company documents before filing suit. Axsome produced documents in September 2025, and the plaintiffs then filed this derivative lawsuit in the Court of Chancery of the State of Delaware.The Court of Chancery ruled that the plaintiffs’ claims were untimely under the doctrine of laches, applying Delaware’s three-year statute of limitations by analogy. The court held that the claims accrued by April 22, 2022, at the latest, and that neither the late and informally served Section 220 demands nor the existence of federal litigation tolled or excused the delay. The Court of Chancery concluded that the mere transmission of books and records demands did not suspend the limitations period, found no extraordinary circumstances to rebut the presumption of prejudice, and dismissed the complaint with prejudice as time-barred. View "In Re Axsome Therapeutics, Inc. Stockholder Derivative Litigation" on Justia Law

An investor in a publicly traded biopharmaceutical company filed a proposed class action against the company and its CEO, alleging securities fraud. The plaintiff claimed that the company misled investors by suggesting that the FDA had approved their methodology for measuring a drug’s efficacy in clinical trials. The alleged misrepresentation was made in a press release that communicated the FDA’s input on the study’s endpoints, but, according to the plaintiff, failed to disclose that the FDA found the methodology unacceptable. When the company later announced it would not use the disputed methodology, the share price initially increased. A decline in the share price occurred over the next two days, during which the stock moved in line with the general market.The United States District Court for the Southern District of New York dismissed the complaint with prejudice, holding that the plaintiff failed to sufficiently plead loss causation, an essential element of a securities fraud claim. The court noted that the share price rose on the day of the corrective disclosure and only declined later, in tandem with the broader market. The district court also denied the plaintiff’s request to amend the complaint, reasoning that amendment would be futile.On appeal, the United States Court of Appeals for the Second Circuit reviewed the district court's dismissal de novo. The appellate court agreed that the plaintiff did not plausibly allege loss causation. It explained that when a stock price does not fall immediately after a corrective disclosure, and a later decline coincides with general market losses, a plaintiff must provide a plausible explanation linking the loss to the alleged fraud. Because the plaintiff failed to do so, the Second Circuit affirmed the district court’s judgment and denial of leave to amend. View "Huey v. Anavex Life Sciences Corporation" on Justia Law

A robotics company, whose primary product is a well-known robot vacuum, agreed in August 2022 to be acquired by a major online retailer. Over the next eighteen months, the companies sought approval for the merger from regulatory authorities in the United States and Europe. In January 2024, facing significant regulatory obstacles, the parties abandoned the merger. Following this, shareholders of the robotics company, led by an investment fund, brought a securities fraud class action against the company’s CEO and CFO. They alleged that during the merger’s review period, company statements misrepresented or omitted material information regarding the likelihood of regulatory approval, particularly concerning the company’s expectation of approval and the acquirer’s cooperation with regulators.The United States District Court for the District of Massachusetts dismissed the amended complaint with prejudice. The court found that the plaintiffs failed to identify any actionable material misrepresentation or omission and did not adequately allege scienter (the intent or knowledge of wrongdoing). During the appeal, the robotics company entered Chapter 11 bankruptcy, resulting in its dismissal from the appeal, which continued as to the individual defendants.The United States Court of Appeals for the First Circuit reviewed the case. It agreed with the district court that the complaint failed to state a claim for most of the statements challenged by the plaintiffs, affirming dismissal as to those. However, the court found that the amended complaint plausibly alleged that an August 24, 2023, proxy statement expressed an opinion about expected regulatory approval while omitting important contrary information regarding European regulatory concerns and the acquirer’s refusal to cooperate. This omission, in the circumstances, was sufficient to state a claim as to that statement. The dismissal was reversed in part and affirmed in part, and the case was remanded for further proceedings. View "Premca Extra Income Fund LP v. Angle" on Justia Law

Gap, a major clothing retailer, launched an initiative in August 2021 to expand plus-size clothing options in its Old Navy stores. The company overestimated customer demand for these larger sizes, resulting in excess inventory that had to be sold at discounts. By early 2022, Gap reduced its in-store plus-size offerings and eventually limited extended sizing to online sales. In May 2022, Gap disclosed that these missteps negatively affected its financial results for the first quarter of the year.Investors who purchased Gap stock between November 24, 2021, and July 11, 2022, filed a putative securities class action in the United States District Court for the Eastern District of New York. They alleged that Gap and two senior executives violated the Securities Exchange Act of 1934 by failing to disclose problems with the initiative in various statements to investors. The district court dismissed the complaint under Rule 12(b)(6), concluding that the plaintiffs did not identify any false or misleading statements or adequately plead that the defendants acted with scienter (intent or recklessness).The United States Court of Appeals for the Second Circuit reviewed the case and affirmed the district court’s dismissal. The appellate court held that the challenged statements—including risk disclosures, earnings call remarks, and press releases—were not false or misleading in context and did not obligate Gap to disclose the problems with the initiative. The court found that the statements at issue were either generic industry risks, unactionable opinions or puffery, or did not give rise to a duty to disclose additional information. The appellate court also concluded that the plaintiffs failed to allege facts supporting a strong inference of scienter and, accordingly, their control-person liability claims under Section 20(a) were properly dismissed. The judgment of the district court was affirmed. View "Smith v. The Gap, Inc." on Justia Law

The case concerns the process for selecting a lead plaintiff in a securities fraud class action brought under the Private Securities Litigation Reform Act (PSLRA). After investors filed federal securities claims against a company and its executives, several parties moved to be appointed as lead plaintiff, including Crain Walnut Shelling, LP. Crain Walnut reported the largest financial losses among the movants and made a prima facie showing of adequacy and typicality, initially making it the presumptive lead plaintiff. However, a competing movant, Universal, challenged Crain Walnut’s adequacy, raising concerns about inaccuracies in Crain Walnut’s filings and inconsistent representations about its ownership and organizational structure. During discovery, further issues arose when Crain Walnut’s representative gave problematic deposition testimony, indicating an unwillingness to comply with potential discovery obligations.The United States District Court for the Northern District of California evaluated these challenges. After initial proceedings and discovery, the district court concluded that the evidence raised doubts about Crain Walnut’s adequacy but initially applied a “genuine and serious doubt” standard. Ultimately, Universal was appointed as lead plaintiff after the district court found that Crain Walnut’s adequacy was rebutted based on the evidence.Crain Walnut then petitioned the United States Court of Appeals for the Ninth Circuit for a writ of mandamus to vacate the district court’s orders. The Ninth Circuit clarified that the correct standard for rebutting the PSLRA’s presumption of adequacy is the preponderance of the evidence, not a lower standard. The appellate court held that, even under the correct standard, the district court did not commit clear error in finding Crain Walnut inadequate, and thus mandamus relief was not warranted. The court therefore denied the petition for writ of mandamus. View "CRAIN WALNUT SHELLING, LP V. UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA" on Justia Law